Among the TKIs used in CML, ponatinib is a third generation BCR::ABL1 TKI designed to overcome TKI resistance caused by T315I mutation in BCR::ABL1. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.